Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ANNX
ANNX | US
5.26
USD-0.32
-5.73%
ANNX | US
About ANNX
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
5.26
Open
5.47
High
5.47
Low
5.21
Annexon Inc. a clinical-stage biopharmaceutical company discovers and develops therapeutics for autoimmune neurodegenerative and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005 a monoclonal antibody which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007 which is in Phase II clinical trials to treat patients with geographic atrophy. In addition it develops ANX105 an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502 an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane California.
View LessANNX | US
Risk
51.5
Sharpe
1.95
Luna's Score
52/100
Recommendation
Hold
Luna says (ANNX | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
61.8%1 month
51.5%3 months
66.9%6 months
68.5%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.23
Debt to equity
0.08
Debt to assets
0.07
Ent. to EBITDA
-2.47
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-124.79M
MarketCap
555.74M
MarketCap(USD)
555.74M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-42.20
Short ratio
6.05
Short perc.
9.85
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.08
Range1M
1.19
Range3M
1.78
Volumes: Market Activity
Rel. volume
0.88
Price X volume
11.06M
